These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1060 related items for PubMed ID: 26121913

  • 1. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B, de Sanjosé S, Tous S, Quiros B, Muñoz N, Bosch X, Alemany L.
    Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
    [Abstract] [Full Text] [Related]

  • 2. Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: A population-based prospective cohort study.
    Bertoli HK, Thomsen LT, Iftner T, Dehlendorff C, Kjær SK.
    Gynecol Oncol; 2020 May; 157(2):456-462. PubMed ID: 32008794
    [Abstract] [Full Text] [Related]

  • 3. Detection and Type-Distribution of Human Papillomavirus in Vulva and Vaginal Abnormal Cytology Lesions and Cancer Tissues from Thai Women.
    Ngamkham J, Boonmark K, Phansri T.
    Asian Pac J Cancer Prev; 2016 May; 17(3):1129-34. PubMed ID: 27039737
    [Abstract] [Full Text] [Related]

  • 4. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
    Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw KL, Dasbach EJ, Kjær SK.
    PLoS One; 2014 May; 9(2):e88323. PubMed ID: 24505474
    [Abstract] [Full Text] [Related]

  • 5. The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
    Lindquist S, Frederiksen K, Petersen LK, Kjær SK.
    Int J Cancer; 2024 Jul 01; 155(1):61-70. PubMed ID: 38418719
    [Abstract] [Full Text] [Related]

  • 6. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.
    Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM.
    Obstet Gynecol; 2009 Apr 01; 113(4):917-924. PubMed ID: 19305339
    [Abstract] [Full Text] [Related]

  • 7. Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile.
    Hampl M, Wentzensen N, Vinokurova S, von Knebel-Doeberitz M, Poremba C, Bender HG, Kueppers V.
    J Cancer Res Clin Oncol; 2007 Apr 01; 133(4):235-45. PubMed ID: 17294241
    [Abstract] [Full Text] [Related]

  • 8. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.
    Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsagué X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Muñoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C.
    Obstet Gynecol; 2018 Aug 01; 132(2):261-270. PubMed ID: 29995724
    [Abstract] [Full Text] [Related]

  • 9. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis.
    De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S.
    Int J Cancer; 2009 Apr 01; 124(7):1626-36. PubMed ID: 19115209
    [Abstract] [Full Text] [Related]

  • 10. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer.
    Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V.
    Obstet Gynecol; 2006 Dec 01; 108(6):1361-8. PubMed ID: 17138767
    [Abstract] [Full Text] [Related]

  • 11. The impact of Germany's human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances.
    Goodman E, Reuschenbach M, Viering T, Luzak A, Greiner W, Hampl M, Jacob C.
    Arch Gynecol Obstet; 2024 Nov 01; 310(5):2639-2646. PubMed ID: 39230793
    [Abstract] [Full Text] [Related]

  • 12. Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status.
    Mpunga T, Chantal Umulisa M, Tenet V, Rugwizangoga B, Milner DA, Munyanshongore C, Heideman DAM, Bleeker MCG, Tommasino M, Franceschi S, Baussano I, Gheit T, Sayinzoga F, Clifford GM.
    Int J Cancer; 2020 Mar 15; 146(6):1514-1522. PubMed ID: 31173641
    [Abstract] [Full Text] [Related]

  • 13. [Nine-valent HPV vaccine - new generation of HPV vaccine].
    Fait T, Dvořák V, Pilka R.
    Ceska Gynekol; 2015 Dec 15; 80(6):397-400. PubMed ID: 26741152
    [Abstract] [Full Text] [Related]

  • 14. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    FUTURE I/II Study GroupDepatment of Laboratory Medicine, Lund University, Malmö, Sweden. joakim.dillner@med.lu.se, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.
    BMJ; 2010 Jul 20; 341():c3493. PubMed ID: 20647284
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
    Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J.
    Lancet; 2007 May 19; 369(9574):1693-702. PubMed ID: 17512854
    [Abstract] [Full Text] [Related]

  • 16. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States.
    Hariri S, Unger ER, Schafer S, Niccolai LM, Park IU, Bloch KC, Bennett NM, Steinau M, Johnson ML, Markowitz LE, HPV-IMPACT Working Group.
    Cancer Epidemiol Biomarkers Prev; 2015 Feb 19; 24(2):393-9. PubMed ID: 25416715
    [Abstract] [Full Text] [Related]

  • 17. HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus.
    Nicolás-Párraga S, Gandini C, Pimenoff VN, Alemany L, de Sanjosé S, Xavier Bosch F, Bravo IG, RIS HPV TT and HPV VVAP study groups.
    Cancer Med; 2016 Oct 19; 5(10):2909-2919. PubMed ID: 27654117
    [Abstract] [Full Text] [Related]

  • 18. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
    Medeiros R, Vaz S, Rebelo T, Figueiredo-Dias M.
    Acta Med Port; 2020 Mar 02; 33(3):198-201. PubMed ID: 32130098
    [Abstract] [Full Text] [Related]

  • 19. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention.
    Forcier M, Musacchio N.
    Dermatol Ther; 2010 Mar 02; 23(5):458-76. PubMed ID: 20868401
    [Abstract] [Full Text] [Related]

  • 20. HR-HPV E6/E7 mRNA In Situ Hybridization: Validation Against PCR, DNA In Situ Hybridization, and p16 Immunohistochemistry in 102 Samples of Cervical, Vulvar, Anal, and Head and Neck Neoplasia.
    Mills AM, Dirks DC, Poulter MD, Mills SE, Stoler MH.
    Am J Surg Pathol; 2017 May 02; 41(5):607-615. PubMed ID: 28403015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.